[Urinary Cytology in Cases of Bladder Cancer: a Critical Evaluation]

Overview

Journal Urologe A

Specialty Urology

Date 2003 Aug 5

PMID 12898033

Citations 7

Authors

P Rathert

Affiliations

Soon will be listed here.

Abstract

Is urinary cytology still a useful method in cases of bladder cancer since additional methods (fluorescence image analysis, monoclonal antibody immunocytology, fibrin degradation products, nuclear matrix protein measurement and others) are under investigation? The literature has been reviewed and compared with classical and new cytology statistics: urinary cytology is less useful than cystoscopy and some of the urine bound tests for the diagnosis of low grade tumors. On the other hand, cytology is extremely valuable for the diagnosis of high grade transitional cell cancers (TCC) and especially carcinomas in situ. The presence of high-grade TCC in the cytology specimen from a patient with low grade papillary TCC suggests either an unrecognised carcinoma in situ or high grade disease in the upper urinary tract or urethra. Urinary cytology is still indispensable in the management of patients with transitional cancer.

Citing Articles

URINE CYTOLOGY AND AXILLARY TESTING FOR INTERPRETATION AND FOLLOW-UP OF URINARY TUMORS.

Kalogeraki A, Tamiolakis D, Mamoulakis C Acta Clin Croat. 2023; 61(3):505-510.

PMID: 37492363 PMC: 10364101. DOI: 10.20471/acc.2022.61.03.16.

The role of collecting bladder wash fluid before biopsy procedure to help the cytological diagnosis of residual tumor.

Kilicarslan A, Sungu N, Balci S, Canda E, Altinova S, Guler G J Cytol. 2015; 32(2):85-9.

PMID: 26229243 PMC: 4520053. DOI: 10.4103/0970-9371.160549.

Correlation between the cytology of urine sediment in fresh sample and smears stained by Papanicolaou and Giemsa methods.

Palaoro L, Angerosa M J Cytol. 2014; 31(1):25-31.

PMID: 25190980 PMC: 4150338. DOI: 10.4103/0970-9371.130666.

[Urine cytology - update 2013. A systematic review of recent literature].

Bohm M, Dorp F, Schostak M, Hakenberg O Urologe A. 2013; 52(9):1207-24.

PMID: 24026058 DOI: 10.1007/s00120-013-3301-7.

[Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?].

Hess J, Tschirdewahn S, Szarvas T, Rossi R, Rubben H, Dorp F Urologe A. 2011; 50(6):702-5.

PMID: 21465088 DOI: 10.1007/s00120-010-2502-6.

References

Ellwein L, Farrow G . Urinary cytology screening: the decision facing the asymptomatic patient. Med Decis Making. 1988; 8(2):110-9. DOI: 10.1177/0272989X8800800207. View

Soloway M, MURPHY W, Johnson D, Farrow G, Paulson D, Garnick M . Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop. Br J Urol. 1990; 66(4):380-5. DOI: 10.1111/j.1464-410x.1990.tb14958.x. View

Lokeshwar V, Soloway M . Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol. 2001; 165(4):1067-77. View

Epstein J, Amin M, Reuter V, Mostofi F . The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22(12):1435-48. DOI: 10.1097/00000478-199812000-00001. View

Retz M, Lehmann J, Wullich B, Stockle M . [After-care of bladder carcinoma]. Urologe A. 2002; 40(6):480-4. DOI: 10.1007/s001200170012. View

Grossfeld G, Litwin M, Wolf J, Hricak H, Shuler C, Agerter D . Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology. 2001; 57(4):599-603. DOI: 10.1016/s0090-4295(01)00919-0. View

Oosterlinck W . The management of superficial bladder cancer. BJU Int. 2001; 87(2):135-40. DOI: 10.1046/j.1464-410x.2001.00948.x. View

Schmitz-Drager B, Goebell P, Ebert T, Fradet Y . p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol. 2000; 38(6):691-9;discussion 700. DOI: 10.1159/000020364. View

Boman H, Hedelin H, Holmang S . Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol. 2001; 167(1):80-3. View

10.

Rubben H, Otto T . [Molecular biology diagnosis of bladder carcinoma]. Urologe A. 2000; 39(2):178-81. DOI: 10.1007/s001200050029. View

11.

Schwalb D, Herr H, Fair W . The management of clinically unconfirmed positive urinary cytology. J Urol. 1993; 150(6):1751-6. DOI: 10.1016/s0022-5347(17)35886-x. View

12.

Wawroschek F, Rathert P . [Urine cytology]. Urologe A. 1995; 34(1):69-75. View

13.

Konety B, Getzenberg R . Urine based markers of urological malignancy. J Urol. 2001; 165(2):600-11. DOI: 10.1097/00005392-200102000-00081. View

14.

Althausen A, Prout Jr G, Daly J . Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976; 116(5):575-80. DOI: 10.1016/s0022-5347(17)58916-8. View

15.

Saad A, Hanbury D, McNicholas T, Boustead G, Woodman A . The early detection and diagnosis of bladder cancer: a critical review of the options. Eur Urol. 2001; 39(6):619-33. DOI: 10.1159/000052519. View

16.

Brown F . Urine cytology. It is still the gold standard for screening?. Urol Clin North Am. 2000; 27(1):25-37. DOI: 10.1016/s0094-0143(05)70231-7. View

17.

MURPHY W, Medina C, Wright N, Wajsman Z . The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol. 1997; 158(6):2102-6. DOI: 10.1016/s0022-5347(01)68167-9. View

18.

Ali-El-Dein B, El-Tabey N, Abdel-Latif M, Abdel-Rahim M, El-Bahnasawy M . Late uro-ileal cancer after incorporation of ileum into the urinary tract. J Urol. 2001; 167(1):84-8. View

19.

Kausch I, Bohle A . Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol. 2001; 39(5):498-506. DOI: 10.1159/000052495. View

20.

PAPANICOLAOU G, Marshall V . URINE SEDIMENT SMEARS AS A DIAGNOSTIC PROCEDURE IN CANCERS OF THE URINARY TRACT. Science. 1945; 101(2629):519-20. DOI: 10.1126/science.101.2629.519. View